The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
In his latest Beyond the Data column, President and CEO Dr. Drew Altman discusses whether Democrats can make the Medicaid and ACA cuts a winning political issue before the midterm elections and before most people feel the cuts.
Every summer, health insurers submit rate filings to state regulators detailing expectations and justifying premium rate changes for ACA-regulated health plans for the coming year. With the enhanced premium tax credits set to expire at the end of 2025, consumers can expect increases in how much they pay for coverage. KFF examines 23 early insurer premium filings from Vermont, Oregon, Washington, and Washington, DC, which include an additional 4 percent increase in premiums, on average,…
In a new column, Dr. Drew Altman, KFF’s President and CEO, discusses the limits of polling on policy, and what we have learned over more than 30 years of polling about how giving people more information and arraying tradeoffs can change opinion, including on the health policy changes and funding cuts in the current reconciliation bill.
The Alliance for Health Reform and the Kaiser Family Foundation co-sponsored this briefing to have a panel of experts answer questions about how public support for health reform waxes and wanes depending, not only on what's being proposed in the reform proposals, but also on who asks the question and how it is asked. Issues addressed include: Do the majority of Americans support health care reform now? Do people want to pay for covering the…
This budget analysis reviews U.S. funding for global health programs in the FY15 Omnibus Appropriations bill, signed into law by the President on December 16, 2014.
As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs. The House-passed bill would allow the federal government to negotiate prices for some high-cost drugs in Medicare, and set a hard cap on out-of-pocket drug spending for Medicare Part D enrollees. For people with Medicare and private insurance, the legislation would limit annual increases in drug prices and cap…
Medicare is likely to be back on the federal policy agenda this year as Congress and President Trump pursue repealing and replacing the Affordable Care Act, and potentially consider options to reduce federal spending. When talking about Medicare, the nation’s federal health insurance program for 57 million people age 65 and over and younger people with disabilities, some policymakers often express concern that the program will soon be “bankrupt” and that rising spending is unsustainable.…
This blog post revisits an earlier analysis of the drug Sovaldi (sofosbuvir) using new data released by the Centers for Medicare and Medicaid Services, and considers both the ongoing impact of hepatitis C drugs for Medicare Part D and the broader implications for Medicare of new high-priced drugs entering the market.
The 2012 Survey of Americans on the U.S. Role in Global Health is the fourth in a series that aims to examine the American public’s views, knowledge and opinions of U.S. efforts to improve health for people in developing countries.
This issue brief analyzes Medicaid spending by state on SDPs that require prior CMS approval to better understand the use of SDPs before new limits in the reconciliation law take effect.
© 2026 KFF